Summary
DexCom, Inc. (DXCM) has filed an 8-K report detailing the official appointment of Jacob S. Leach as President and Chief Executive Officer, effective January 1, 2026. This transition follows Mr. Leach's service as interim principal executive officer during Kevin R. Sayer's medical leave. The filing outlines the key terms of Mr. Leach's new role, including an annual base salary of $1,150,000 and a target bonus opportunity of 150% of his base salary. Furthermore, Mr. Leach will receive significant equity awards, comprising restricted stock units valued at $7,500,000 and performance stock units with a target value of $7,500,000, both vesting over several years and contingent on continued service and performance conditions. This leadership change represents a pivotal moment for DexCom as it moves forward under new permanent executive leadership. Investors will be keen to observe Mr. Leach's strategic direction and execution in his permanent CEO role, especially considering the substantial incentive package designed to align his interests with long-term shareholder value. The report also confirms that Kevin R. Sayer is expected to return from his medical leave around March 2026, with Mark Foletta continuing as interim Chairman of the Board until then.
Key Highlights
- 1Jacob S. Leach officially appointed President and CEO, effective January 1, 2026.
- 2Mr. Leach's new annual base salary will be $1,150,000.
- 3He will have an annual target bonus opportunity of 150% of his base salary.
- 4Mr. Leach to receive $7,500,000 in restricted stock units (RSUs) vesting over three years.
- 5Mr. Leach to receive $7,500,000 in performance stock units (PSUs) tied to specific performance conditions.
- 6Kevin R. Sayer is anticipated to return from medical leave around March 2026.
- 7Mark Foletta will continue as interim Chairman of the Board until Mr. Sayer's return.